Autonomix Medical, Inc. announced on May 15, 2025, that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,257,071, titled 'Controlled sympathectomy and micro-ablation systems and methods.' This patent strengthens the company's intellectual property position in the nerve-mapping and denervation space.
The newly issued patent covers advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation technologies, designed to provide enhanced precision in treating nerve-related conditions. Key features protected include deployable microfingers with embedded sensors for real-time physiological monitoring and the ability to map, stimulate, ablate, and assess nerve activity within a single integrated system.
This technology also supports feedback-driven control of various procedures and adaptive modulation to adjust therapeutic output based on real-time inputs. The patent is a vital addition to Autonomix's expanding portfolio, which includes over 80 issued patents and 40 pending applications, as the company aims to revolutionize the treatment of neurological conditions such as chronic pain and hypertension.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.